DETECTION AND QUANTIFICATION OF MINORITY KRAS SUBCLONES IN TUMORS USING DROPLET-BASED MICROFLUIDICS: CLINICAL IMPLICATION

D. Pekin¹,², C. Normand³, S. Kotsopoulos³, X. Li³, L. Benhaim⁴, O. Bouché⁴, T. Lecompte⁵, D. Le Corre⁴, T. Hor¹, Z. El Harrak¹, P. Nizard¹, D. Link³, J.B. Hutschinson³, P. Laurent-Puig¹ and V. Taly¹

¹Université Paris Descartes, INSERM-S775, France
²Université de Strasbourg, CNRS UMR 7006, France
³Raindance Technologies, Lexington Massachusetts, USA
⁴CHU de Reims, Reims, France.
⁵Université de Tours, Tours, France

ABSTRACT

We used a multiplex droplet-based digital PCR method in a retrospective study including 181 patients with a metastatic colorectal cancer (mCRC) for the quantitative and sensitive detection of KRAS and BRAF mutations in DNA extracted from tumors.

KEYWORDS: digital PCR (dPCR), KRAS mutations, cancer biomarkers, droplet-based microfluidics

INTRODUCTION

Colorectal cancer is the 3rd most common cancer worldwide [1]. 1 million patients are diagnosed each year and 50% of them will eventually develop a metastatic disease [2]. Recent efforts to improve the treatment of metastatic colorectal cancer has led to the development of monoclonal antibodies such as Cetuximab (or its fully humanized version Panitumumab) that inhibit the activation of the Epidermal Growth Factor Receptor (EGFR) and its downstream pathways that promote cell growth, proliferation and the inhibition of apoptosis. Mutations in the KRAS and BRAF genes are found at high rates in colon cancers and are correlated with the non-response to anti-EGFR therapies. However, only 50% of patients with apparently non-mutated tumors give an objective response to treatment [3] and for most of these patients a secondary resistance invariably ensues, the cause of which remains poorly understood. The presence of a small subpopulation of cells with mutated genes within the tumor, undetected by conventional procedures can be the cause of these treatment resistances.

THEORY

Up to date the most widely used technique for the assessment of KRAS mutational status in clinical samples is the direct sequencing. This technique offers a sensitivity of 20% (mutant alleles represent at least 20% of the total DNA in the sample for the detection to be reproducible) [4]. Most of the studies aimed at the determination of the predictive role of KRAS mutations in the response to anti-EGFR therapies used allele-specific PCR (qPCR), which has a sensitivity of 10% [5]. Quantitative procedures with a higher sensitivity for the detection of mutations in the KRAS and BRAF genes are required in order to determine if the apparently non-mutated tumors are indeed carriers of subpopulations with mutated genes. The required sensitivity can be obtained with the use of digital PCR techniques coupled with microfluidic systems [6].

EXPERIMENTAL

We previously described a picodroplet-based microfluidic technique for the highly sensitive and quantitative detection of KRAS mutations in biological samples [7,8] able to detect up to 1/200,000 mutant DNA in wild-type DNA. We subsequently adapted this technique in a multiplexed format for the quantitative detection of the 7 common mutations of KRAS (in codon 12 and 13) (Fig.1) and applied it to the detection of circulating tumor DNA in plasma samples from patients with a metastatic colorectal cancer [9].
Figure 1: Multiplex detection of the seven most frequent mutations of the KRAS gene: TaqMan assays for each of the seven most frequent mutations of KRAS (G13D, G12R, G12D, G12V, G12A, G12S and G12C) were assembled in two multiplexed panels by mixing mutation-specific VIC and/or FAM probes in tuned concentrations with a single wild-type specific VIC probe in each panel. The tuning of the probe concentrations allows to discriminate between droplets containing no amplifiable fragments, wild-type KRAS DNA or a DNA fragment with a unique KRAS mutation.

We now applied this procedure for the screening of DNA extracted from tumors of patients (108 men, 73 women with 62 years of age ± 11) with a metastatic disease, all refractory to conventional chemotherapy (Irinotecan) and treated with anti-EGFR combined with Irinotecan or as monotherapy.

RESULTS AND DISCUSSION
Tumors of 43 patients were already characterized as bearing a KRAS mutation by conventional TaqMan analysis. These were detected as positives in droplets with proportions of mutated DNA from 11 to 64% (mean of 38.2% ± 16.5%). Within the 138 negative tumors, 23 were found positive in droplets with KRAS proportions from 0.01% to 12.4% (mean of 2.1% ± 3.2%). Among the mutated tumors, additional subclones were detected only in droplets. Thanks to the enhancement of sensitivity provided by the use of droplet digital PCR coupled with microfluidics we were able to observe an inverse correlation between the amount of mutated DNA and the response to anti-EGFR treatment (Fig. 2, P<0.0001). The Progression Free Survival of patients with tumor presenting less than 5% mutated KRAS was comparable to those of patients with non-mutated tumors.

Figure 2: Fraction of mutated DNA for patients who present complete or partial responses (CR and PR); Stable disease (SD) or progressive disease (PD). Response to anti-EGFR therapy correlates with the proportion of mutated DNA in tumors.
CONCLUSION

Our results demonstrate the importance of a quantitative approach for the detection of low frequency KRAS mutations within tumor samples for the therapeutic management of patients. With the quantitativity and the higher sensitivity provided by droplet-based microfluidics, we also show that the amount of mutated DNA is indicative of the response to treatment and the survival of patients.

ACKNOWLEDGEMENTS

Deniz Pekin was supported by fellowships from the « Region Alsace ». This work was supported by the Ministère de l’Enseignement Supérieur et de la Recherche, the Université Paris-Descartes, the Université de Strasbourg, the Centre National de la Recherche Scientifique (CNRS), the Institut National de la Santé et de la Recherche Médicale (INSERM), the Institut National du Cancer (INCA, n° 2009-1-RT-03-US-1 and 2009-RT-03-UP5-1), the Association pour la recherche contre le cancer (ARC, no. SL220100601375) and the Agence Nationale de la Recherche (ANR Nanobiotechnologies).

REFERENCES: